menu
    • menu
    [{"orgOrder":0,"company":"Kymab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"KY1005","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kymab \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymab \/ Not Applicable"},{"orgOrder":0,"company":"Kymab","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymab","amount2":1.45,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":1.45,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kymab \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymab \/ Sanofi"},{"orgOrder":0,"company":"Kymab","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymab","amount2":1.45,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":1.45,"dosageForm":"","sponsorNew":"Kymab \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymab \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals by Kymab

    Menu

    Kymab

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kymab

                            United Kingdom
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $1,450.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi Completes Kymab Acquisition

                            Details : Sanofi gains Kymab's KY1005 (Amlitelimab) to its pipeline, a fully human monoclonal antibody targeting key immune system regulator OX40L. Kymab’s pipeline also includes the oncology asset KY1044.

                            Brand Name : KY1005

                            Molecule Type : Large molecule

                            Upfront Cash : $1,100.0 million

                            April 09, 2021

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $1,450.0 million

                            Deal Type : Acquisition

                            Kymab cb

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kymab

                            United Kingdom
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $1,450.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi to Acquire Kymab, Adding KY1005 to Its Pipeline, a Human Monoclonal Antibody Targeting Key Immune Syste...

                            Details : The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. KY1005 binds to OX40-Ligand and has the potential to treat a varieties of immune-mediated diseases and infl...

                            Brand Name : KY1005

                            Molecule Type : Large molecule

                            Upfront Cash : $1,100.0 million

                            January 11, 2021

                            Lead Product(s) : Amlitelimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $1,450.0 million

                            Deal Type : Acquisition

                            Kymab cb

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kymab

                            United Kingdom
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KY1005

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis

                            Details : A clinically meaningful improvement in disease activity was found compared to placebo, as measured by percentage of change from baseline in the Eczema Area and Severity Index (EASI) in patients inadequately controlled by topical corticosteroids from base...

                            Brand Name : KY1005

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 11, 2020

                            Lead Product(s) : KY1005

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Kymab cb

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth